PURPOSE: The decision to start venovenous extracorporeal membrane oxygenation (VV ECMO) is commonly based on the severity of respiratory failure, with little consideration of the extrapulmonary organ function. The aim of the study was to identify predictors of mortality and to develop a score allowing a better stratification of patients at the time of VV ECMO initiation. METHODS: This was a prospective multicenter cohort study on 60 patients with influenza A (H1N1)-associated respiratory distress syndrome participating in the Italian ECMOnet data set in the 2009 pandemic. Criteria for ECMO institution were standardized according to national guidelines. RESULTS: The survival rate in patients treated with ECMO was 68 %. Significant predictors of death before ECMO institution by multivariate analysis were hospital length of stay before ECMO institution (OR = 1.52, 95 % CI 1.12-2.07, p = 0.008); bilirubin (OR = 2.32, 95 % CI 1.52-3.52, p < 0.001), creatinine (OR = 7.38, 95 % CI 1.43-38.11, p = 0.02) and hematocrit values (OR = 0.82, 95 % CI 0.72-0.94, p = 0.006); and mean arterial pressure (OR = 0.92, 95 % CI 0.88-0.97, p < 0.001). The ECMOnet score was developed based on these variables, with a score of 4.5 being the most appropriate cutoff for mortality risk prediction. The high accuracy of the ECMOnet score was further confirmed by ROC analysis (c = 0.857, 95 % CI 0.754-0.959, p < 0.001) and by an independent external validation analysis (c = 0.694, 95 % CI 0.562-0.826, p = 0.004). CONCLUSIONS: Mortality risk for patients receiving VV ECMO is correlated to the extrapulmonary organ function at the time of ECMO initiation. The ECMOnet score is a tool for the evaluation of the appropriateness and timing of VV ECMO in acute lung failure.
PURPOSE: The decision to start venovenous extracorporeal membrane oxygenation (VV ECMO) is commonly based on the severity of respiratory failure, with little consideration of the extrapulmonary organ function. The aim of the study was to identify predictors of mortality and to develop a score allowing a better stratification of patients at the time of VV ECMO initiation. METHODS: This was a prospective multicenter cohort study on 60 patients with influenza A (H1N1)-associated respiratory distress syndrome participating in the Italian ECMOnet data set in the 2009 pandemic. Criteria for ECMO institution were standardized according to national guidelines. RESULTS: The survival rate in patients treated with ECMO was 68 %. Significant predictors of death before ECMO institution by multivariate analysis were hospital length of stay before ECMO institution (OR = 1.52, 95 % CI 1.12-2.07, p = 0.008); bilirubin (OR = 2.32, 95 % CI 1.52-3.52, p < 0.001), creatinine (OR = 7.38, 95 % CI 1.43-38.11, p = 0.02) and hematocrit values (OR = 0.82, 95 % CI 0.72-0.94, p = 0.006); and mean arterial pressure (OR = 0.92, 95 % CI 0.88-0.97, p < 0.001). The ECMOnet score was developed based on these variables, with a score of 4.5 being the most appropriate cutoff for mortality risk prediction. The high accuracy of the ECMOnet score was further confirmed by ROC analysis (c = 0.857, 95 % CI 0.754-0.959, p < 0.001) and by an independent external validation analysis (c = 0.694, 95 % CI 0.562-0.826, p = 0.004). CONCLUSIONS: Mortality risk for patients receiving VV ECMO is correlated to the extrapulmonary organ function at the time of ECMO initiation. The ECMOnet score is a tool for the evaluation of the appropriateness and timing of VV ECMO in acute lung failure.
Authors: Moronke A Noah; Giles J Peek; Simon J Finney; Mark J Griffiths; David A Harrison; Richard Grieve; M Zia Sadique; Jasjeet S Sekhon; Daniel F McAuley; Richard K Firmin; Christopher Harvey; Jeremy J Cordingley; Susanna Price; Alain Vuylsteke; David P Jenkins; David W Noble; Roxanna Bloomfield; Timothy S Walsh; Gavin D Perkins; David Menon; Bruce L Taylor; Kathryn M Rowan Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: Marilyn C Morris; Richard F Ittenbach; Rodolfo I Godinez; Joel D Portnoy; Sarah Tabbutt; Brian D Hanna; Timothy M Hoffman; J William Gaynor; James T Connelly; Mark A Helfaer; Thomas L Spray; Gil Wernovsky Journal: Crit Care Med Date: 2004-04 Impact factor: 7.598
Authors: Andrew Davies; Daryl Jones; Michael Bailey; John Beca; Rinaldo Bellomo; Nikki Blackwell; Paul Forrest; David Gattas; Emily Granger; Robert Herkes; Andrew Jackson; Shay McGuinness; Priya Nair; Vincent Pellegrino; Ville Pettilä; Brian Plunkett; Roger Pye; Paul Torzillo; Steve Webb; Michael Wilson; Marc Ziegenfuss Journal: JAMA Date: 2009-10-12 Impact factor: 56.272
Authors: Gernot Beutel; Olaf Wiesner; Matthias Eder; Carsten Hafer; Andrea S Schneider; Jan T Kielstein; Christian Kühn; Albert Heim; Tina Ganzenmüller; Hans-Heinrich Kreipe; Axel Haverich; Andreas Tecklenburg; Arnold Ganser; Tobias Welte; Marius M Hoeper Journal: Crit Care Date: 2011-03-02 Impact factor: 9.097
Authors: Nicolò Patroniti; Alberto Zangrillo; Federico Pappalardo; Adriano Peris; Giovanni Cianchi; Antonio Braschi; Giorgio A Iotti; Antonio Arcadipane; Giovanna Panarello; V Marco Ranieri; Pierpaolo Terragni; Massimo Antonelli; Luciano Gattinoni; Fabrizio Oleari; Antonio Pesenti Journal: Intensive Care Med Date: 2011-07-06 Impact factor: 17.440
Authors: Thomas Müller; Stephan Schroll; Alois Philipp; Christian Karagiannidis; Matthias Amann; Dirk Lunz; Julia Langgartner; Thomas Bein; Marcus Fischer; Matthias Lubnow Journal: Intensive Care Med Date: 2013-05-22 Impact factor: 17.440
Authors: Arthur W Baker; Michael B Edmond; Loreen A Herwaldt; Luke F Chen; Sudha Srikantaswamy; Daniel J Sexton Journal: Ann Am Thorac Soc Date: 2017-12
Authors: Jeffrey DellaVolpe; Ryan P Barbaro; Jeremy W Cannon; Eddy Fan; Wendy R Greene; Kyle J Gunnerson; Lena M Napolitano; Ace Ovil; Jeremy C Pamplin; Matthieu Schmidt; Lauren R Sorce; Daniel Brodie Journal: Crit Care Med Date: 2020-06 Impact factor: 7.598